


## PHARMACEUTICAL 2022

Immix Biopharma Inc. Rank 451 of 475







## Immix Biopharma Inc. Rank 451 of 475

The relative strengths and weaknesses of Immix Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immix Biopharma Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 571% points. The greatest weakness of Immix Biopharma Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 1,005% points.

The company's Economic Capital Ratio, given in the ranking table, is -861%, being 585% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	18,186
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	202
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-6.5
Other Expenses	6.0
Other Liabilities	0
Other Net Income	-23,026
Property and Equipment	5.7
Research and Development	127
Revenues	0
Selling, General and Administrative Expense	1,225

Output Variable	Value in 1000 USD
Assets	18,192
Liabilities	202
Expenses	1,358
Stockholders Equity	17,990
Net Income	-24,384
Comprehensive Net Income	-24,387
Economic Capital Ratio	-861%

